Allogeneic cell therapy manufacturing market Top Companies - Lonza Group, KBI Biopharma, Inc., Waisman Biomanufacturing, Cell, and Gene Therapy Catapult.

Global Allogeneic Cell Therapy Manufacturing Market to Record An Exponential CAGR of 17% By 2030.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Global Allogeneic Cell Therapy Manufacturing Market Trends, Industry Competition Analysis, Revenue, and Forecast to 2030."

According to the latest market research study, the global allogeneic cell therapy manufacturing market is valued at US$ 869.6 million, and it is expected to reach US$ 3424.1 million by 2030 with a CAGR of 17% during a forecast period.

Get Free Access to Demo Report, Excel Pivot and ToC :https://www.insightaceanalytic.com/request-sample/1194

Allogeneic cell therapy products are yielding promising preclinical and clinical results. Allogeneic cell treatments are developed utilizing healthy cells from unrelated donors, and they rely on a single source of cells to treat vast numbers of patients. It is a process in which a patient receives healthy cells (stem cells) from a donor to replace damaged or destroyed ones.
Several factors, including the rising burden of chronic diseases such as cancer, diabetes, and cardiovascular disease, increased government funding for stem cell therapies, a growing elderly population, developing healthcare infrastructure, technological advancements, and rising public awareness about the benefits of allogeneic cell therapies, are expected to drive demand for allogeneic cell therapy manufacturing during the forecast period. Many pharmaceutical companies are introducing allogeneic cell treatments to treat patients with chronic disorders. For example, in March 2021, Adicet Bio, Inc., a biotechnology company researching allogeneic gamma delta T cell treatments for cancer and other disorders, commenced its First-in-Human Phase I clinical trial investigating ADI-001 for the treatment of B cell non-Hodgkin's lymphoma (NHL). ADI-001 is an investigational first-in-class allogeneic gamma delta T cell therapy that expresses a chimeric antigen receptor (CAR) targeting CD20, with the potential to increase selective tumor targeting, aid adaptive and innate anti-tumor immune responses, and improve persistence for strong activity in patients. Due to the growing demand for cost-effective and efficient cell and gene therapies, outsourced contract research organizations (CROs) have increased their bioassay services, raising market growth potential in the near future.

Expert Knowledge, Just a Click Away:https://calendly.com/insightaceanalytic/30min?month=2024-02

However, high development costs and immunological rejection difficulties may limit the growth of the global allogeneic cell therapy manufacturing market in the approaching years.

North America is expected to dominate this market during the forecast period (2019-2030), followed by Europe and Asia-Pacific, owing to increased R&D spending in cell therapy research, a high prevalence of chronic diseases, and rapid acceptance of sophisticated technologies.
Lonza Group, KBI Biopharma, Inc., Waisman Biomanufacturing, Cell, and Gene Therapy Catapult, Thermo Fisher Scientific, Inc., Merck KGaA, Catalent Inc., Oxford Biomedica Plc, Fujifilm Cellular Dynamics, Inc., Wuxi Apptec, Charles River Laboratories International, Inc., The Discovery Labs LLC, ABL, Inc., BioCentriq, Commercializing Living Therapies, and Other Prominent Player among

Some significant developments in the market:
• In January 2022, Mesoblast Limited (Australi), a global leader in allogeneic cellular medicines for inflammatory diseases, presented 36-month follow-up results from thecPhase 3 trial of its allogeneic cell therapy rexlemestrocel-L (MPC-06-ID) in patients with CLBP (chronic low back pain) associated with DDD (degenerative disc disease). This trial showed a durable reduction in back pain lasting at least three years from a single intra-discal injection of rexlemestrocel-L+hyaluronic acid (HA) carrier.
• In November 2021, BONE THERAPEUTICS (Belgium), the cell therapy company, and Link Health Pharma Co., Ltd signed a non-binding term sheet for the global rights for ALLOB, allogeneic bone cell therapy of Bone Therapeutics'.
• In September 2021, Adaptimmune Therapeutics (UK) partnered with Roche Group (Genentech), to develop and commercialize allogeneic cell therapy for the treatment of multiple cancer indications.

Unlock Your GTM Strategy:https://www.insightaceanalytic.com/customisation/1194

Market Segments
Allogeneic Cell Therapy Manufacturing Market, by Product, 2019-2030 (Value US$ Mn)
• Induced pluripotent stem cells (iPSC)
• T-cells and Natural killer (NK) cells
• Human pluripotent stem cells (hPSCs)
• Mesenchymal stem cells (MSC)
• β-cells
• Neurons
• Immortalized and engineered cell lines
• Tissue engineered product
Allogeneic Cell Therapy Manufacturing Market, by By Scale of Operation, 2019-2030 (Value US$ Mn)
• Preclinical Scale Operations
• Clinical Scale Operations
• Commercial Scale Operations
Allogeneic Cell Therapy Manufacturing Market, by Region, 2019-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/1194

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.